Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resis...
Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely...
Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, discusses study results of talazoparib vs chemotherapy in patients with BRCA1/2-mutated HER2-negative advanced breast canc...
Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced non–small cell lung cancer and brai...
Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pemetrexed plus platinum—whi...
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women with no history of cancer. ...
Byoung Chul Cho, MD, PhD, of Yonsei Cancer Center and Severance Hospital, discusses the STK11 and KEAP1 mutations in non–small cell lung cancers, and their relationship to the efficacy of pembrolizuma...
Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number of tobacco and vape shops, ...
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a...
Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation–positive advanced melanoma. His te...
Steven J. O’Day, MD, of the John Wayne Cancer Institute, discusses phase II results for the combination of pembrolizumab with a novel innate immune activator, Imprime PGG, as second-line treatment for...
Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with high-risk HER2-negative stage...